MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP
Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...